❌

Normal view

Received — 2 April 2026 ⏭

Predicting Neuromodulation Outcome for Parkinson's Disease with Generative Virtual Brain Model

✇cs.AI, q-bio.NC updates on arXiv.org
By: Siyuan Du · Siyi Li · Shuwei Bai · Ang Li · Haolin Li · Mingqing Xiao · Yang Pan · Dongsheng Li · Weidi Xie · Yanfeng Wang · Ya Zhang · Chencheng Zhang · Jiangchao Yao
1 April 2026 at 12:00
arXiv:2603.29176v1 Announce Type: new Abstract: Parkinson's disease (PD) affects over ten million people worldwide. Although temporal interference (TI) and deep brain stimulation (DBS) are promising therapies, inter-individual variability limits empirical treatment selection, increasing non-negligible surgical risk and cost. Previous explorations either resort to limited statistical biomarkers that are insufficient to characterize variability, or employ AI-driven methods which is prone to overfitting and opacity. We bridge this gap with a pretraining-finetuning framework to predict outcomes directly from resting-state fMRI. Critically, a generative virtual brain foundation model, pretrained on a collective dataset (2707 subjects, 5621 sessions) to capture universal disorder patterns, was finetuned on PD cohorts receiving TI (n=51) or DBS (n=55) to yield individualized virtual brains with high fidelity to empirical functional connectivity (r=0.935). By constructing counterfactual estimations between pathological and healthy neural states within these personalized models, we predicted clinical responses (TI: AUPR=0.853; DBS: AUPR=0.915), substantially outperforming baselines. External and prospective validations (n=14, n=11) highlight the feasibility of clinical translation. Moreover, our framework provides state-dependent regional patterns linked to response, offering hypothesis-generating mechanistic insights.

AGFT: Alignment-Guided Fine-Tuning for Zero-Shot Adversarial Robustness of Vision-Language Models

✇cs.AI, q-bio.NC updates on arXiv.org
By: Yubo Cui · Xianchao Guan · Zijun Xiong · Zheng Zhang
1 April 2026 at 12:00
arXiv:2603.29410v1 Announce Type: cross Abstract: Pre-trained vision-language models (VLMs) exhibit strong zero-shot generalization but remain vulnerable to adversarial perturbations. Existing classification-guided adversarial fine-tuning methods often disrupt pre-trained cross-modal alignment, weakening visual-textual correspondence and degrading zero-shot performance. In this paper, we propose an Alignment-Guided Fine-Tuning (AGFT) framework that enhances zero-shot adversarial robustness while preserving the cross-modal semantic structure. Unlike label-based methods that rely on hard labels and fail to maintain the relative relationships between image and text, AGFT leverages the probabilistic predictions of the original model for text-guided adversarial training, which aligns adversarial visual features with textual embeddings via soft alignment distributions, improving zero-shot adversarial robustness. To address structural discrepancies introduced by fine-tuning, we introduce a distribution consistency calibration mechanism that adjusts the robust model output to match a temperature-scaled version of the pre-trained model predictions. Extensive experiments across multiple zero-shot benchmarks demonstrate that AGFT outperforms state-of-the-art methods while significantly improving zero-shot adversarial robustness.

LaSM: Layer-wise Scaling Mechanism for Defending Pop-up Attack on GUI Agents

✇cs.AI, q-bio.NC updates on arXiv.org
By: Zihe Yan · Zhuosheng Zhang · Jiaping Gui · Gongshen Liu
1 April 2026 at 12:00
arXiv:2507.10610v2 Announce Type: replace-cross Abstract: Graphical user interface (GUI) agents built on multimodal large language models (MLLMs) have recently demonstrated strong decision-making abilities in screen-based interaction tasks. However, they remain highly vulnerable to pop-up-based environmental injection attacks, where malicious visual elements divert model attention and lead to unsafe or incorrect actions. Existing defense methods either require costly retraining or perform poorly under inductive interference. In this work, we systematically study how such attacks alter the attention behavior of GUI agents and uncover a layer-wise attention divergence pattern between correct and incorrect outputs. Based on this insight, we propose \textbf{LaSM}, a \textit{Layer-wise Scaling Mechanism} that selectively amplifies attention and MLP modules in critical layers. LaSM improves the alignment between model saliency and task-relevant regions without additional training. Extensive experiments across multiple datasets demonstrate that our method significantly improves the defense success rate and exhibits strong robustness, while having negligible impact on the model's general capabilities. Our findings reveal that attention misalignment is a core vulnerability in MLLM agents and can be effectively addressed through selective layer-wise modulation. Our code can be found in https://github.com/YANGTUOMAO/LaSM.

Robust transcriptomic hallmarks targeting intratumor heterogeneity in intrahepatic cholangiocarcinoma

✇(Multiomics OR Omics) AND (Pancreatic)
By: Youpei Lin · Lihua Peng · Haichao Zhao · Penghui Lin · Lv Chen · Zunyun Gong · Jian Lin · Dongbing Liu · Xupeng Yang · Xiangze Song · Mao Zhang · Shuyi Ji · Junhua Rao · Huijuan Luo · Yifei Cheng · Xiaofang Chen · Guohe Song · Hao Hou · Dongning Rao · Tiancheng Zhang · Weiren Liu · Shu Zhang · Gaoyang Xu · Juan Zhang · Liyun Xiao · Yan Liang · Yang Liu · Yuhan Chen · Zhirou Cui · Xiaoying Wang · Jian Zhou · Qiang Gao · Kui Wu · Jia Fan
31 March 2026 at 18:00

Cell Rep Med. 2026 Mar 30:102708. doi: 10.1016/j.xcrm.2026.102708. Online ahead of print.

ABSTRACT

Intratumor heterogeneity (ITH) undermines transcriptome-based stratification in intrahepatic cholangiocarcinoma (iCCA). Here, we integrate multi-omics data from multi-region, single-region, and single-cell RNA sequencing cohorts to systematically characterize gene expression ITH. We uncover that immune and stromal heterogeneity are primary drivers of ITH, leading to misclassification of a median 27.8% of tumors by existing subtyping systems. To overcome this, we identify a low-intratumor-heterogeneity/high-intertumor-variability (LIHV) gene set and develop an ITH-insensitive classification system defining five subgroups: inflammatory (SI), metabolic (SII), atypical (SIII-1), immune-silent (SIII-2), and neurodegenerative (SIII-3). These subgroups exhibit distinct clinical outcomes, molecular features, immune landscapes, and therapeutic vulnerabilities. GPRC5A and VTCN1 serve as robust immunohistochemical biomarkers for SI and SIII tumors, while serum CEA and CA19-9 identify inflammatory iCCA. Therapeutically, HSP90 inhibition synergizes with anti-PD1 in inflammatory iCCA, whereas combined anti-PD1 and anti-TIM3 suppresses neurodegenerative iCCA. Collectively, our study provides a robust molecular framework and actionable therapeutic strategies for iCCA.

PMID:41916296 | DOI:10.1016/j.xcrm.2026.102708

Dynamic Targetable Extracellular Vesicle Surface Proteins Monitor Depth of Response to CAR T Therapy

✇MRD
By: Chen Zhao · Lei Qiu · Ning An · Yong Ju · Jacqueline Ziqian Yang · Hyoyong Kim · Ryan Y Zhang · Junseok Lee · Jingjing He · Liang-Yan Chen · Yaya Xu · Yue Ma · Emily Ren · Sophie Pan · Pranay Sashikanth · Jina Kim · Di Wang · Peiling Zhang · Jianlin Hu · Yang Gao · Yuhan Bao · Yanhua Tu · Li Wang · Zhili Wang · Zhicheng Zhang · Renjun Pei · Edwin M Posadas · Sungyong You · Wanxing Chai-Ho · Tasha L Lin · Sarah M Larson · Dinesh S Rao · Hsian-Rong Tseng · Na Sun · Chunrui Li · Yazhen Zhu
27 March 2026 at 18:00

Res Sq [Preprint]. 2026 Mar 18:rs.3.rs-8913641. doi: 10.21203/rs.3.rs-8913641/v1.

ABSTRACT

Extracellular vesicles (EVs) represent a promising liquid biopsy platform in multiple myeloma (MM). We developed an MM EV Surface Protein Assay to quantify and dynamically monitor four MM EV subpopulations defined by targetable MM surface proteins (BCMA, CD38, GPRC5D, and CD319) across 336 serial blood samples from 45 relapsed/refractory MM (RRMM) patients treated with anti-BCMA chimeric antigen receptor (CAR) T-cell therapy. All four MM EV subpopulations significantly decreased in 43 patients with initial response, while BCMA+, GPRC5D+, and CD319+ MM EVs increased in 19 patients with progression, and antigen escape was detected by BCMA+ MM EVs. MM EV subpopulations differentiated minimal residual disease (MRD) status and complemented MRD for detecting early relapse before clinical progression. Notably, CD319+ MM EVs were early predictors of progression-free and overall survival in MRD-negative patients. This assay enables noninvasive monitoring of deep response, progression, and antigen escape, and stratifies survival in MRD-negative patients with RRMM.

PMID:41890853 | PMC:PMC13015583 | DOI:10.21203/rs.3.rs-8913641/v1

There are no more articles
❌